BBLGW
Closed
Bone Biologics Corp Warrants
15.
0 (0.00%)
Last Update: 30 Jun 2025 16:30:00
Yesterday: 15.
Day's Range: 15. - 15.
Send
sign up or login to leave a comment!
When Written:
0.04
Bone Biologics Corp warrants are financial instruments that give the holder the right, but not the obligation, to purchase shares of Bone Biologics Corp at a predetermined price and during a specific period of time. These warrants are traded on the NASDAQ Capital Market under the ticker symbol BONEW.
The exercise price of Bone Biologics Corp warrants is $11.50 per share, and they expire on February 4, 2026. The company issued these warrants as part of a public offering in February 2021, which raised $12.5 million in gross proceeds.
Investors who hold Bone Biologics Corp warrants have the potential to profit if the company's stock price rises above the exercise price. However, if the stock price remains below the exercise price, the warrants may expire worthless.
It is important to note that investing in warrants can be risky and speculative, and investors should carefully consider their financial goals and risk tolerance before investing.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The exercise price of Bone Biologics Corp warrants is $11.50 per share, and they expire on February 4, 2026. The company issued these warrants as part of a public offering in February 2021, which raised $12.5 million in gross proceeds.
Investors who hold Bone Biologics Corp warrants have the potential to profit if the company's stock price rises above the exercise price. However, if the stock price remains below the exercise price, the warrants may expire worthless.
It is important to note that investing in warrants can be risky and speculative, and investors should carefully consider their financial goals and risk tolerance before investing.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!